How Analysts Feel About Lannett Company, Inc. (LCI) After Achieving 52 Week Low?

July 16, 2018 - By Jack Shaw

Investors sentiment decreased to 1.18 in Q1 2018. Its down 0.20, from 1.38 in 2017Q4. It worsened, as 29 investors sold Lannett Company, Inc. shares while 36 reduced holdings. 24 funds opened positions while 53 raised stakes. 36.15 million shares or 1.94% less from 36.87 million shares in 2017Q4 were reported.
Us Commercial Bank De reported 0% stake. Ls Advsrs Ltd Liability Com stated it has 914 shares or 0% of all its holdings. Bridgeway holds 0.02% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 145,000 shares. Millennium Mngmt Lc holds 0% or 42,709 shares. Bluemountain Capital Management Limited Com reported 10,793 shares. Aqr Mgmt Ltd Liability Co holds 101,027 shares or 0% of its portfolio. Gargoyle Investment Advisor Lc reported 13,420 shares. Sei Invests reported 0% stake. Schwab Charles Inv Management has 0% invested in Lannett Company, Inc. (NYSE:LCI). Moreover, Sg Americas Ltd Liability has 0% invested in Lannett Company, Inc. (NYSE:LCI). 84,807 are held by Bowling Management Limited Liability Corp. Moreover, Thompson Siegel & Walmsley has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 188 shares. Connor Clark & Lunn Investment Management holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 48,677 shares. Acadian Asset Mngmt Ltd Co invested in 97 shares. Tiaa Cref Investment holds 0% or 66,082 shares.

Since May 10, 2018, it had 2 buys, and 0 insider sales for $407,710 activity. 2,000 shares were bought by Crew Timothy C, worth $29,460.

The stock of Lannett Company, Inc. (NYSE:LCI) hit a new 52-week low and has $11.33 target or 9.00 % below today’s $12.45 share price. The 8 months bearish chart indicates high risk for the $473.28M company. The 1-year low was reported on Jul, 16 by If the $11.33 price target is reached, the company will be worth $42.59M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 8.46% or $1.15 during the last trading session, reaching $12.45. About 720,963 shares traded or 3.39% up from the average. Lannett Company, Inc. (NYSE:LCI) has declined 16.75% since July 16, 2017 and is downtrending. It has underperformed by 29.32% the S&P500.

Analysts await Lannett Company, Inc. (NYSE:LCI) to report earnings on August, 22. They expect $0.65 EPS, up 62.50 % or $0.25 from last year’s $0.4 per share. LCI’s profit will be $24.71 million for 4.79 P/E if the $0.65 EPS becomes a reality. After $0.80 actual EPS reported by Lannett Company, Inc. for the previous quarter, Wall Street now forecasts -18.75 % negative EPS growth.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Among 4 analysts covering Lannett (NYSE:LCI), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Lannett had 4 analyst reports since January 24, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 7 by Roth Capital. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Market Perform” rating by BMO Capital Markets on Thursday, February 8.

More recent Lannett Company, Inc. (NYSE:LCI) news were published by: which released: “20 Small-Cap Stocks With the Potential for Outsized Gains” on July 12, 2018. Also published the news titled: “3 Top Healthcare Stocks to Buy Right Now” on June 28, 2018.‘s news article titled: “Lannett (LCI) Falls as Deutsche Bank Addresses the ‘Elephant in the Room'” with publication date: June 18, 2018 was also an interesting one.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company has market cap of $473.28 million. The firm offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It has a 10.34 P/E ratio. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout.

Lannett Company, Inc. (NYSE:LCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.